肿瘤细胞上存在一种名为“PD-L1”的蛋白,这个“小兵”极具迷惑性,会让免疫检查点PD-1误以为肿瘤细胞是“自己人”,进而不去攻击肿瘤细胞,使它逃脱了免疫系统的灭杀。 于是,在面对肿瘤攻击时,人们迫切需要为PD-1配置一名帮手,纠正它...
[2] Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022, 13: 964442. doi: 10.3389/fimmu.2022.964442. [3] Wang Y, Zhou S, Yang F, et al. Trea...
联合其他检测以解决PD-L1检测本身的局限性是未来免疫治疗疗效预测标志物发展的可行方向。 参考文献 1. Deborah Blythe Doroshow, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. 2. Hossein Borghaei, et al. Pembrolizumab plus...
PD-1/PD-L1通路阻断剂，包括PD-1单克隆抗体(纳武单抗nivolumab,帕博丽珠单抗pembrolizumab，西米单抗cemiplimab)以及PD-L1单克隆抗体(阿特珠单抗atezolizumab,阿维鲁单抗avelumab,德瓦鲁单抗durvalumab)是包括黑色素瘤、乳腺癌、结直肠癌、非小细胞肺癌、小细胞肺癌、肾细胞癌、皮肤鳞状细胞癌以及血液系统肿瘤在内的多种...
参考文献 [1]. FerraraR, Mezquita L, Texier M, et al. Hyperprogressive disease in patients withadvanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or withsingle-agent chemotherapy. JAMA Oncol 2018;4:1543–52 [2]. ChampiatS, Ferrara R, Massard C, et al. ...
et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep 10, 2083 (2020). 编辑于 2021-08-10 20:43 PD-L1 免疫治疗 癌症免疫疗法...
1.D. B. Doroshow et al., PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18, 345-362 (2021).2. R. S. Finn et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382, 1894-1905 (2020).3. L. Paz-Ares et...
AKTOUDIANAKIS EvangelosCHO AesopGRAUPE MichaelLAD Lateshkumar ThakorlalMACHICAO TELLO Paulo A.MEDLEY Jonathan WilliamMETOBO Samuel E.NADUTHAMBI DevanPHILLIPS Barton W.MONOVICH Scott Preston
而且它们的半衰期通常很短，降低了产生不良影响的机会。基于这些特点，在癌症免疫治疗领域开发基于小分子的策略引起了广泛的兴趣，其未来的前景仍然广阔而令人兴奋。参考文献：1.Immune-checkpoint inhibitors: long-termimplications of toxicity. Nat Rev Clin Oncol. 2022 Jan 26 : 1–14.（转自：凯莱英Asymchem）
17 款 PD-1/PD-L1/CTLA-4 免疫抑制剂，一图讲全！免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）为代表的免疫疗法通过激活患者自身 T 淋巴细胞的抗肿瘤免疫功能，发挥杀灭肿瘤细胞的作用，在临床上已被广泛使用。ICIs 作为针对细胞毒性 T 淋巴细胞相关抗原 4（cytotoxic T-lymphocyte-associated protein 4...